ID   OV-2008
AC   CVCL_0473
AS   CVCL_4066
SY   OV2008; Ov2008; OV 2008; 2008; A2008
DR   BTO; BTO:0003792
DR   MCCL; MCC:0000371
DR   BioSample; SAMN03151841
DR   BioSample; SAMN03151843
DR   cancercelllines; CVCL_0473
DR   ChEMBL-Cells; CHEMBL3308015
DR   ChEMBL-Targets; CHEMBL612818
DR   Cosmic; 849613
DR   Cosmic; 948293
DR   Cosmic; 988874
DR   Cosmic; 1102825
DR   Cosmic; 1524359
DR   Cosmic; 1707563
DR   Cosmic; 2582806
DR   Cosmic; 2674703
DR   GEO; GSM184384
DR   GEO; GSM184385
DR   GEO; GSM659387
DR   GEO; GSM711715
DR   GEO; GSM711718
DR   GEO; GSM851907
DR   GEO; GSM851925
DR   IARC_TP53; 25074
DR   Progenetix; CVCL_0473
DR   PubChem_Cell_line; CVCL_0473
DR   Wikidata; Q54936825
RX   PubMed=4118903;
RX   PubMed=9234707;
RX   PubMed=11314036;
RX   PubMed=19926575;
RX   PubMed=22710073;
RX   PubMed=24023729;
RX   PubMed=25846456;
CC   Problematic cell line: Contaminated. Shown to be a ME-180 derivative (PubMed=22710073). Originally thought to originate from a female patient with an ovarian serous carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00466.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=25846456).
CC   Transformant: NCBI_TaxID; 45240; Human papillomavirus type 68 (HPV68).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Omentum; UBERON=UBERON_0003688.
ST   Source(s): PubMed=22710073
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 12,13
ST   D18S51: 12
ST   D19S433: 13,15.2
ST   D21S11: 30,31
ST   D2S1338: 18
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 9,10
ST   D8S1179: 14
ST   FGA: 23
ST   TH01: 8,9.3
ST   TPOX: 8,10
ST   vWA: 15,17
DI   NCIt; C27676; Human papillomavirus-related cervical squamous cell carcinoma
DI   ORDO; Orphanet_213767; Squamous cell carcinoma of the cervix uteri
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1401 ! ME-180
SX   Female
AG   66Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 32
RX   PubMed=4118903; DOI=10.1016/0002-9378(72)90109-3;
RA   DiSaia P.J., Sinkovics J.G., Rutledge F.N., Smith J.P.;
RT   "Cell-mediated immunity to human malignant cells. A brief review and
RT   further studies with two gynecologic tumors.";
RL   Am. J. Obstet. Gynecol. 114:979-989(1972).
RX   PubMed=9234707; DOI=10.1128/mcb.17.8.4501;
RA   Bullions L.C., Notterman D.A., Chung L.S., Levine A.J.;
RT   "Expression of wild-type alpha-catenin protein in cells with a mutant
RT   alpha-catenin gene restores both growth regulation and tumor
RT   suppressor activities.";
RL   Mol. Cell. Biol. 17:4501-4508(1997).
RX   PubMed=11314036; DOI=10.1038/sj.onc.1204211;
RA   Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L.,
RA   Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R.,
RA   Minna J.D.;
RT   "Searching for microsatellite mutations in coding regions in lung,
RT   breast, ovarian and colorectal cancers.";
RL   Oncogene 20:1005-1009(2001).
RX   PubMed=19926575; DOI=10.1309/AJCPTK87EMMIKPFS;
RA   DeRycke M.S., Andersen J.D., Harrington K.M., Pambuccian S.E.,
RA   Kalloger S.E., Boylan K.L.M., Argenta P.A., Skubitz A.P.N.;
RT   "S100A1 expression in ovarian and endometrial endometrioid carcinomas
RT   is a prognostic indicator of relapse-free survival.";
RL   Am. J. Clin. Pathol. 132:846-856(2009).
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
RX   PubMed=24023729; DOI=10.1371/journal.pone.0072162;
RA   Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M.,
RA   Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R.,
RA   Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.;
RT   "Type-specific cell line models for type-specific ovarian cancer
RT   research.";
RL   PLoS ONE 8:E72162-E72162(2013).
RX   PubMed=25846456; DOI=10.3892/ijo.2015.2951;
RA   Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M.,
RA   Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.;
RT   "Profiling of actionable gene alterations in ovarian cancer by
RT   targeted deep sequencing.";
RL   Int. J. Oncol. 46:2389-2398(2015).